Federal Register / Vol. 62, No. 8 / Monday, January 13, 1997 / Notices 1767

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. Once the application has

been accepted for processing, it will also

be available for inspection at the offices

of the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act,

including whether the acquisition of the

nonbanking company can ‘‘reasonably

be expected to produce benefits to the

public, such as greater convenience,

increased competition, or gains in

efficiency, that outweigh possible

adverse effects, such as undue

concentration of resources, decreased or

unfair competition, conflicts of

interests, or unsound banking practices’’

(12 U.S.C. 1843). Any request for

a hearing must be accompanied by a

statement of the reasons a written

presentation would not suffice in lieu of

a hearing, identifying specifically any

questions of fact that are in dispute,

summarizing the evidence that would

be presented at a hearing, and indicating

how the party commenting would be

aggrieved by approval of the proposal.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than February 7,

1997.

A. Federal Reserve Bank of Atlanta

(Zane R. Kelley, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303:

1. Community Bancorp of Louisiana,

Inc., Raceland, Louisiana; to merge with

American Security Bancshares, Inc.,

Welsh, Louisiana, and thereby

indirectly acquire American Bank,

Welsh, Louisiana.

B. Federal Reserve Bank of Chicago

(James A. Bluemle, Vice President) 230

South LaSalle Street, Chicago, Illinois

60690:

1. Damen Financial Corporation,

Schaumburg, Illinois; to become a bank

holding by acquiring 100 percent of the

voting shares of Damen National Bank,

Schaumburg, Illinois (in organization).

Board of Governors of the Federal Reserve

System, January 7, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–692 Filed 1–10–97; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES

ADMINISTRATION

Information Security Oversight Office;

Cancellation of Optional Form

AGENCY: General Services

Administration.

ACTION: Notice.

SUMMARY: Because of low usage the

following Optional Form is cancelled:

OF 95, Opened/Locked Sign for

Restricted Files.

DATES: Effective January 13, 1997.

FOR FURTHER INFORMATION CONTACT:

Ms. Barbara Williams, General Services

Administration, (202) 501–0581.

Dated: December 23, 1996.

Steven Garfinkel,

Director, Information Security Oversight

Office.

[FR Doc. 97–713 Filed 1–10–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96D–0300]

Reviewer Guidance for a Premarket

Notification Submission for Blood

Establishment Computer Software;

Availability

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

availability of a guidance document

entitled ‘‘Reviewer Guidance for a

Premarket Notification Submission for

Blood Establishment Computer

Software.’’ The guidance document

applies to blood establishment software

products intended for use in the

manufacture of blood and blood

components or for the maintenance of

data that blood establishment personnel

use in making decisions regarding the

suitability of donors and the release of

blood or blood components for

transfusion or further manufacture. The

guidance presents an overview of the

type of information, including methods

and procedures, that FDA’s reviewers

should expect to be included in 510(k)

submissions for such devices and

describes the approach FDA’s reviewers

should take in reviewing premarket

submissions for blood establishment

computer software.

DATES: Written comments may be

submitted at any time, however, to

ensure comments are considered for the

next revision they should be submitted

by April 14, 1997.

ADDRESSES: Submit written comments

and information to the Dockets

Management Branch (HFA–305), Food

and Drug Administration, 12420

Parklawn Dr., rm. 1–23, Rockville, MD

20857. Submit written requests for

single copies of the guidance entitled

‘‘Reviewer Guidance for a Premarket

Notification Submission for Blood

Establishment Computer Software’’ to

the Office of Communication, Training,

and Manufacturers Assistance (HFM–

40), Center for Biologics Evaluation and

Research, Food and Drug

Administration, 1401 Rockville Pike,

Rockville, MD 20852–1448. Send one

self-addressed adhesive label to assist

that office in processing your requests.

The document may also be obtained

by calling the CBER Voice Information

System at 1–800–835–4709 or 301–827–

1800, or FAX at 1–800–CBER–FAX, or

301–827–3844.

Persons with access to the INTERNET

may obtain the document using the

World Wide Web (WWW), or bounceback e-mail. For WWW access, connect

to CBER at ‘‘http.fda.gov/cber/

cberftp.html’’. To receive the document

by bounce-back e-mail, send a message

to ‘‘SWREVIEW@al.cber.fda.gov’’.

FOR FURTHER INFORMATION CONTACT:

Nancy J. Jensen, Office of Blood

Research and Review/Division of Blood

Applications, Center for Biologics

Evaluation and Research (HFM–385),

Food and Drug Administration, 1401

Rockville Pike, Rockville, MD 20852–

1448, 301–827–3524.

SUPPLEMENTARY INFORMATION: FDA is

announcing the availability of a